-
Something wrong with this record ?
Active transforming growth factor-β2 in the aqueous humor of posterior polymorphous corneal dystrophy patients
A. Stadnikova, L. Dudakova, P. Skalicka, Z. Valenta, M. Filipec, K. Jirsova,
Language English Country United States
Document type Journal Article
NLK
Directory of Open Access Journals
from 2006
Free Medical Journals
from 2006
Public Library of Science (PLoS)
from 2006
PubMed Central
from 2006
Europe PubMed Central
from 2006
ProQuest Central
from 2006-12-01
Open Access Digital Library
from 2006-10-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-01-01
Medline Complete (EBSCOhost)
from 2008-01-01
Nursing & Allied Health Database (ProQuest)
from 2006-12-01
Health & Medicine (ProQuest)
from 2006-12-01
Public Health Database (ProQuest)
from 2006-12-01
ROAD: Directory of Open Access Scholarly Resources
from 2006
- MeSH
- Corneal Dystrophies, Hereditary metabolism MeSH
- Glaucoma metabolism MeSH
- Keratoplasty, Penetrating methods MeSH
- Aqueous Humor metabolism MeSH
- Middle Aged MeSH
- Humans MeSH
- Cornea metabolism MeSH
- Endothelium, Corneal metabolism MeSH
- Transforming Growth Factor beta2 metabolism MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
PURPOSE: Posterior polymorphous corneal dystrophy (PPCD) is characterized by abnormal proliferation of corneal endothelial cells. It was shown that TGF-β2 present in aqueous humor (AH) could help maintaining the corneal endothelium in a G1-phase-arrest state. We wanted to determine whether the levels of this protein are changed in AH of PPCD patients. METHODS: We determined the concentrations of active TGF-β2 in the AH of 29 PPCD patients (42 samples) and 40 cadaver controls (44 samples) by ELISA. For data analysis the PPCD patients were divided based on either the molecular genetic cause of their disease as PPCD1 (37 samples), PPCD3 (1 sample) and PPCDx (not linked to a known PPCD loci, 4 samples) or on the presence (17 samples) or absence (25 samples) of secondary glaucoma or on whether they had undergone penetrating keratoplasty (PK, 32 samples) or repeated PK (rePK, 7 samples). RESULTS: The level of active TGF-β2 in the AH of all PPCD patients (mean ± SD; 386.98 ± 114.88 pg/ml) in comparison to the control group (260.95 ± 112.43 pg/ml) was significantly higher (P = 0.0001). Compared to the control group, a significantly higher level of active TGF-β2 was found in the PPCD1 (P = 0.0005) and PPCDx (P = 0.0022) groups. Among patients the levels of active TGF-β2 were not significantly affected by gender, age, secondary glaucoma or by the progression of dystrophy when one or repeated PK were performed. CONCLUSION: The levels of active TGF-β2 in the AH of PPCD patients are significantly higher than control values, and thus the increased levels of TGF-β2 could be a consequence of the PPCD phenotype and can be considered as another feature characterizing this disease.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17023139
- 003
- CZ-PrNML
- 005
- 20170720122211.0
- 007
- ta
- 008
- 170720s2017 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1371/journal.pone.0175509 $2 doi
- 035 __
- $a (PubMed)28414732
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Stadnikova, Andrea $u Laboratory of the Biology and Pathology of the Eye, Institute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic.
- 245 10
- $a Active transforming growth factor-β2 in the aqueous humor of posterior polymorphous corneal dystrophy patients / $c A. Stadnikova, L. Dudakova, P. Skalicka, Z. Valenta, M. Filipec, K. Jirsova,
- 520 9_
- $a PURPOSE: Posterior polymorphous corneal dystrophy (PPCD) is characterized by abnormal proliferation of corneal endothelial cells. It was shown that TGF-β2 present in aqueous humor (AH) could help maintaining the corneal endothelium in a G1-phase-arrest state. We wanted to determine whether the levels of this protein are changed in AH of PPCD patients. METHODS: We determined the concentrations of active TGF-β2 in the AH of 29 PPCD patients (42 samples) and 40 cadaver controls (44 samples) by ELISA. For data analysis the PPCD patients were divided based on either the molecular genetic cause of their disease as PPCD1 (37 samples), PPCD3 (1 sample) and PPCDx (not linked to a known PPCD loci, 4 samples) or on the presence (17 samples) or absence (25 samples) of secondary glaucoma or on whether they had undergone penetrating keratoplasty (PK, 32 samples) or repeated PK (rePK, 7 samples). RESULTS: The level of active TGF-β2 in the AH of all PPCD patients (mean ± SD; 386.98 ± 114.88 pg/ml) in comparison to the control group (260.95 ± 112.43 pg/ml) was significantly higher (P = 0.0001). Compared to the control group, a significantly higher level of active TGF-β2 was found in the PPCD1 (P = 0.0005) and PPCDx (P = 0.0022) groups. Among patients the levels of active TGF-β2 were not significantly affected by gender, age, secondary glaucoma or by the progression of dystrophy when one or repeated PK were performed. CONCLUSION: The levels of active TGF-β2 in the AH of PPCD patients are significantly higher than control values, and thus the increased levels of TGF-β2 could be a consequence of the PPCD phenotype and can be considered as another feature characterizing this disease.
- 650 _2
- $a komorová voda $x metabolismus $7 D001082
- 650 _2
- $a rohovka $x metabolismus $7 D003315
- 650 _2
- $a dědičné dystrofie rohovky $x metabolismus $7 D003317
- 650 _2
- $a rohovkový endotel $x metabolismus $7 D004728
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a glaukom $x metabolismus $7 D005901
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a keratoplastika perforující $x metody $7 D015948
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a transformující růstový faktor beta2 $x metabolismus $7 D053781
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Dudakova, Lubica $u Laboratory of the Biology and Pathology of the Eye, Institute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic.
- 700 1_
- $a Skalicka, Pavlina $u Department of Ophthalmology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic.
- 700 1_
- $a Valenta, Zdenek $u Department of Medical Informatics & Biostatistics, Institute of Computer Science, Czech Academy of Sciences, Prague, Czech Republic.
- 700 1_
- $a Filipec, Martin $u European Eye Clinic Lexum, Prague, Czech Republic.
- 700 1_
- $a Jirsova, Katerina $u Laboratory of the Biology and Pathology of the Eye, Institute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic.
- 773 0_
- $w MED00180950 $t PloS one $x 1932-6203 $g Roč. 12, č. 4 (2017), s. e0175509
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28414732 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170720 $b ABA008
- 991 __
- $a 20170720122704 $b ABA008
- 999 __
- $a ok $b bmc $g 1238820 $s 984052
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 12 $c 4 $d e0175509 $e 20170417 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
- LZP __
- $a Pubmed-20170720